Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LumiraDx Ltd LMDXF

Healthcare Medical Devices
LumiraDx Limited is a point of care diagnostic company. The Company is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The Company has developed and launched the LumiraDx Platform, which is an integrated system comprised of a small, versatile Instrument, low-cost microfluidic Test Strips, and seamless,... see more

Recent & Breaking News (PINL:LMDXF)

LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test

GlobeNewswire December 14, 2022

Latest Clinicians' U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers

GlobeNewswire December 8, 2022

LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test

GlobeNewswire November 14, 2022

LumiraDx Reports Third Quarter 2022 Results

GlobeNewswire November 9, 2022

LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9

GlobeNewswire November 2, 2022

LumiraDx Reports Second Quarter 2022 Results

GlobeNewswire August 18, 2022

LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18

GlobeNewswire August 11, 2022

LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement

PR Newswire July 21, 2022

LumiraDx Announces Proposed Public Offering of Common Shares

PR Newswire July 19, 2022

LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System

PR Newswire June 9, 2022

LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete

PR Newswire June 8, 2022

LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test

PR Newswire June 2, 2022

LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform

PR Newswire May 26, 2022

LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test

PR Newswire May 20, 2022

LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking

PR Newswire May 19, 2022

LumiraDx Reports First Quarter 2022 Results

PR Newswire May 11, 2022

LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 11

PR Newswire April 29, 2022

LumiraDx Reports Fourth Quarter and Full Year 2021 Results

PR Newswire March 10, 2022

LumiraDx to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Quarterly Conference Call on March 10

PR Newswire March 3, 2022

LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering

PR Newswire March 1, 2022